First MammaPrint® distribution agreement for Latin-America
Amsterdam, The Netherlands, November 15th, 2006
Agendia B.V. (Amsterdam, The Netherlands) and Teva & Tuteur (Buenos Aires, Argentina) a leading Argentinean Pharmaceutical and Diagnostic company have signed a distribution agreement that provides Teva & Tuteur with the exclusive rights for MammaPrint® in Argentina and Paraguay.

In 2002 a 70-gene tumor expression profile was established as a powerful predictor of disease outcome in breast cancer patients. To facilitate its use in a diagnostic setting, the 70-gene prognosis profile was translated into a customized microarray named MammaPrint®. MammaPrint® clearly demonstrated that microarray technology can be used as a reliable diagnostic tool in the prognosis of breast cancer. The test is therefore an excellent tool to predict outcome of disease in breast cancer patients.

Dr. Laura van 't Veer, Chief Operating Officer at Agendia comments: 'Using the MammaPrint® microarray test in the clinical setting provides more accurate information on recurrence risk as compared to conventional clinical criteria and thus improves patients management for women diagnosed with breast cancer. As a direct result, many patients get the appropriate treatment leading to improved outcome or reduced side effects thus improving quality of life and reducing healthcare costs'.

Dr. Bernard Sixt, Chief Executive Officer at Agendia comments: 'After the successful introduction of Mammaprint® in Europe Agendia's priority is now to make the test globally available to breast cancer patients and clinicians. For that reason we as Agendia are putting a lot of resources and efforts behind this global introduction of MammaPrint®. This is clearly an exciting time for us and also an important step in opening more markets. We are very encouraged by the growing interest and demand of clinicians all over the world.'

=============================================================
About Agendia
Agendia is world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test - MammaPrint® - that predicts the chance of breast cancer recurrence. CupPrint®*, the second product in the market of Agendia, is used for the identification of Cancers of Unknown Primary. Agendia maintains close ties with NKI/AVL, ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.

*CupPrint is based on a license to the TUO database of AviaraDx.
More information about Agendia BV is available at www.agendia.com